
Pliant slumps on decision to pause lung disease drug trial
Shares in Pliant plunged after the US biotech revealed that a safety signal led it to pause a trial of its idiopathic pulmonary fibrosis drug.

Industry steps up as EU debates an action plan for AI
Corporations, investment groups, and technology providers have teamed up in a new project that aims to "unlock Europe's full potential" in AI.

FDA clears new antibiotic for superbug infections
AbbVie has won FDA approval for Emblaveo, a new antibiotic to treat pathogens that pose serious public health threats.

Share in cystic fibrosis firm Sionna rise sharply after IPO
Sionna has closed its IPO, raising $191m for cystic fibrosis candidates that it thinks could be more effective than rivals from Vertex.

NIH indirect funding cuts appals medical research groups
Billions of dollars will be cut from medical research funding provided by the NIH in the latest money-saving programme from the Trump administration.
Partner Content

7th Neuroimmunology Drug Development Summit
7th Neuroimmunology Drug Development Summit | February 25-27 2025 | Boston, MA

3rd Precision Medicine in Inflammatory Bowel Disease Summit ...
Following a year of exceptional progress in IBD drug development, fierce competition in clinical trials for Chron’s Disease and Ulcerative Colitis remains high, and it’s time for biopharma to push

15th World Clinical Biomarkers & Companion Diagnostics Summi...
As recent advances in small molecules, ADCs, cell, and gene therapies poise novel precision therapies from the bench to the clinic, the 15th World Clinical Biomarkers & Companion Diagno

AI Literacy for Pharma Marketing Career Success
Preparing for AI Success in 2025 and Beyond: Insights from Our 2024 Research.

Datapharm partners with phactMI to enhance medicines informa...
Datapharm, a leading medicines information solution provider in Europe, is delighted to announce its expansion into the United States (US) through a new partnership with the Pharma Collabor